<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02850484</url>
  </required_header>
  <id_info>
    <org_study_id>MCPE15003M3</org_study_id>
    <nct_id>NCT02850484</nct_id>
  </id_info>
  <brief_title>A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers With Charcoal Block</brief_title>
  <official_title>A Single-Dose, Randomized, Open-Label, 2-Treatment, 3-Period, 3-Sequence, 3-Way Crossover, Partial Replicate, Oral Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers With Charcoal Block</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intech Biopharm Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intech Biopharm Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this pivotal study is to evaluate the relative bioavailability of SYN010 HFA
      Inhaler and Symbicort 160/4.5μg in healthy volunteers with charcoal block.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A pivotal, single-dose, randomized, open-label, partial replicate, three-period,
      three-sequence, two-treatment, three-way crossover, comparative bioavailability study.

      Ninety-nine, male and female volunteers, 20-45 years of age, with a body mass index (BMI)
      within 18.5-30.0 kg/m2, inclusive, will be enrolled. (The body weight should be over 50 kg,
      inclusive, respectively)

      A single dose of 8 puffs (equivalent to budesonide 1280 μg/formoterol fumarate dihydrate 36
      μg) in each study period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Curve (AUC)</measure>
    <time_frame>Pre-dose and at 0.03, 0.08, 0.17, 0.25, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 and 36 hours after dosing.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>Pre-dose and at 0.03, 0.08, 0.17, 0.25, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 and 36 hours after dosing.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to reach Maximum plasma concentration (Tmax)</measure>
    <time_frame>Pre-dose and at 0.03, 0.08, 0.17, 0.25, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 and 36 hours after dosing.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure (BP)</measure>
    <time_frame>Pre-dose and at 0.5, 16, 24 and 36 hours after dosing.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body temperature (BT)</measure>
    <time_frame>Pre-dose and at 0.5, 16, 24 and 36 hours after dosing.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse rate (PR)</measure>
    <time_frame>Pre-dose and at 0.5, 16, 24 and 36 hours after dosing.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Asthma</condition>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Reference 1 Symbicort Inhaler 160/4.5μg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reference 1: Symbicort Inhaler (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SYN010 HFA Inhaler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SYN010 HFA (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference 2 Symbicort Inhaler 160/4.5μg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reference 2: Symbicort Inhaler (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>Inhaled corticosteroid</description>
    <arm_group_label>Reference 1 Symbicort Inhaler 160/4.5μg</arm_group_label>
    <arm_group_label>SYN010 HFA Inhaler</arm_group_label>
    <arm_group_label>Reference 2 Symbicort Inhaler 160/4.5μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol</intervention_name>
    <description>Long Acting Beta Agonist (LABA)</description>
    <arm_group_label>Reference 1 Symbicort Inhaler 160/4.5μg</arm_group_label>
    <arm_group_label>SYN010 HFA Inhaler</arm_group_label>
    <arm_group_label>Reference 2 Symbicort Inhaler 160/4.5μg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male and female volunteers, aged 20-45, inclusive.

          2. BMI that is within 18.5-30.0 kg/m², inclusive. (The body weight should be over 50 kg,
             inclusive, respectively)

          3. Healthy or Non Clinical Significant, according to the medical history,
             Electrocardiography (ECG), Chest X-ray and physical examination as determined by the
             Principal Investigator/Sub-Investigator.

          4. Systolic blood pressure between 90-139 mmHg, inclusive, and diastolic blood pressure
             between 50-90 mmHg, inclusive, and pulse rate between 50-100 bpm, inclusive and
             temperature between 35.0-37.4°C.

          5. Clinical laboratory values within reference range or Non-Clinical Significance (NCS)
             judged by the Principal Investigator/Sub-Investigator.

          6. Ability to comprehend and be informed of the nature of the study. Capable of giving
             written informed consent prior to receiving any study medication. Must be able to
             communicate effectively with clinic staff.

          7. Ability to fast for at least 14 hours and to consume standard meals.

          8. Availability to volunteer for the entire study duration and willing to adhere to all
             protocol requirements.

          9. Agree not to have a tattoo or body piercing until the end of the study.

         10. Female subjects must fulfill at least one of the following:

               -  Be surgically sterile for a minimum of 6 months;

               -  Post-menopausal for a minimum of 1 year;

               -  Agree to avoid pregnancy and use medically acceptable method of contraception
                  from screening day until 30 days after study has ended (last study procedure).

        Exclusion Criteria:

          1. Known history or presence of any clinically significant hepatic (e.g. active liver
             disease, hepatic impairment), renal/genitourinary (e.g. renal impairment),
             gastrointestinal, cardiovascular, cerebrovascular, pulmonary, endocrine (e.g.
             hypothyroidism), immunological, musculoskeletal (e.g. myopathy, rhabdomyolysis),
             neurological, psychiatric, dermatological or hematological disease or condition unless
             determined as not clinically significant by the Principal
             Investigator/Sub-Investigator.

          2. Clinically significant history or presence of any clinically significant
             gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel disease),
             unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), or other conditions
             known to interfere with the absorption, distribution, metabolism or excretion of the
             drug experienced within 7 days prior to first drug administration, as determined by
             the Principal Investigator/Sub- Investigator.

          3. Presence of any clinically significant illness within 30 days prior to first dosing,
             as determined by the Principal Investigator/Sub-Investigator.

          4. Presence of any significant physical or organ abnormality as determined by the
             Principal Investigator/Sub-Investigator.

          5. A positive test result for any of the following: Human immunodeficiency virus (HIV),
             Hepatitis B surface antigen, Hepatitis C, drugs of abuse (amphetamines, barbiturates,
             benzodiazepines, cocaine, opiates, phencyclidine, tetrahydrocannabinol), breath
             alcohol test. Positive pregnancy test for female subjects.

          6. Known history or presence of:

               -  Alcohol abuse or dependence within one year prior to first drug administration;

               -  Drug abuse or dependence;

               -  Hypersensitivity or idiosyncratic reaction to budesonide, formoterol fumarate
                  dihydrate , its excipients, and/or related substances;

               -  Food allergies and/or presence of any dietary restrictions;

               -  Severe allergic reactions (e.g. anaphylactic reactions, angioedema).

          7. Intolerance to and/or difficulty with blood sampling through venipuncture.

          8. Abnormal diet patterns (for any reason) during the four weeks preceding the study,
             including fasting, high protein diets etc.

          9. Individuals who have donated, in the days prior to first drug administration:

               -  Less than 250 mL of blood in the previous 60 days

               -  300 mL or more in the previous 90 days

         10. Donation of plasma by plasmapheresis within 7 days prior to first drug administration.

         11. Individuals who have participated in another clinical trial and received an
             investigational drug within 30 days prior to first drug administration.

         12. Consumption of food or beverages containing caffeine/methylxanthines, poppy seeds
             and/or alcohol within 48 hours before dosing and containing grapefruit and/or pomelo
             within 10 days prior to first drug administration.

         13. Use of any prescription medication within 30 days prior to first drug administration.

         14. Use of any over-the-counter medications (including oral multivitamins, herbal and/or
             dietary supplements) within 30 days prior to first drug administration (except for
             spermicidal/barrier contraceptive products).

         15. Females taking oral or transdermal hormonal contraceptives within 30 days prior to
             first drug administration.

         16. Females having used implanted, injected, intravaginal, or intrauterine hormonal
             contraceptive within 6 months prior to first drug administration.

         17. Individuals having undergone any major surgery within 6 months prior to the start of
             the study, unless deemed otherwise by Principal Investigator/Sub-Investigator.

         18. Known history of smoking or using tobacco products, nicotine products (patches, gum
             etc.) within 6 months prior to first drug administration.

         19. Pregnant/lactating women.

         20. Subjects will be given training to ensure that subjects are able to correctly use the
             investigational products in screening. The subjects who are unable to operate the
             investigational products proficiently will not be included in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen K Chang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Pharmacology Unit of Mackay Memorial Hospital Tamshui Branch</affiliation>
  </overall_official>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2016</study_first_submitted>
  <study_first_submitted_qc>July 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2016</study_first_posted>
  <last_update_submitted>July 27, 2016</last_update_submitted>
  <last_update_submitted_qc>July 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
    <mesh_term>Charcoal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

